Watching
HURN · Huron Consulting Group Inc.
Updated ·
Against its published line
Above its line on the last close.
How to read this
The red mark is the published kill line — the price that would prove the thesis wrong. The dot is where the name closed on 30 October 2026; a dot left of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row reads well clear, with a hollow dot to show the figure is off the drawn scale. Rows run tightest first.
Kill line
A daily close below $175, which would give back the move above the prior 52-week high of $185.58 by a clear margin. Organic revenue growth in the mid-single digits or lower, or guidance cut below $1.85 billion, would also end the case.
Not a pickResearch coverage at low conviction. A medium-or-higher call would open a pick on the scoreboard.
Catalyst (in 3 days)
How picks are graded →The thesis
Huron Consulting Group's shares closed at a 52-week high of $193.35 on 22 October 2026, and the third-quarter report on 3 November 2026 decides whether organic growth supports a price that now sits above the analyst average target. The rally rests on the 28 July 2026 raise of 2026 revenue before reimbursable expenses (RBR) guidance to $1.85–1.89 billion. Huron has issued no new results or guidance since then.
The narrative is accelerating: the shares rose from $167.05 on 9 October 2026 to $193.35 on 22 October 2026, and company news dated 22 October 2026 reports that Huron will replace Supernus Pharmaceuticals in an S&P index. The 14-day relative strength index (RSI, a 0–100 momentum gauge) reads 84.0, and the shares gained 66.0% over three months. A daily close below $175 would end the case.
Bullish and bearish views on Huron Consulting Group Inc.
The bull case on Huron Consulting Group Inc. (HURN), in brief: Organic demand held in the second quarter. The bear case: The price has passed the analyst average.
Bull case
- Organic demand held in the second quarter. Huron reported second-quarter 2026 RBR of $465.6 million, up 15.7% year over year, including 10.8% organic growth (Huron earnings release, 28 July 2026). The third quarter shows whether that pace continues.
- Guidance rose above the Street. On 28 July 2026 Huron raised RBR guidance from $1.780–1.860 billion to $1.850–1.890 billion against a $1.827 billion analyst estimate, and raised adjusted diluted earnings per share (EPS) guidance to $9.00–9.40 from $8.35–9.15 (Benzinga, 28 July 2026). Second-quarter adjusted EPS was $2.46 against a $2.17 estimate.
- Margins rose with revenue. Second-quarter adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) was $72.6 million, or 15.6% of RBR (Huron earnings release, 28 July 2026).
- An index addition adds a new class of buyer. Company news on 22 October 2026 reports Huron will replace Supernus Pharmaceuticals in an S&P index; the same notice lists 27 October 2026 as the effective date for the MSG Rangers addition to the S&P SmallCap 600. Funds that track an index typically buy added shares around the effective date, which is a view and would be wrong if the shares fall through the date.
Bear case
- The price has passed the analyst average. TipRanks listed four analysts with a $190.75 average target, a $215 high and a $160 low on 9 October 2026; the 22 October 2026 close of $193.35 is above that average. Truist's Buy target of $175 (29 July 2026) is also below the close.
- Momentum is stretched. The RSI of 84.0 on 22 October 2026 and a 66.0% three-month gain show a market that has already moved sharply ahead of the report. Index-related buying can fade once the change takes effect.
- Acquisitions inflate headline growth. Huron's 28 July 2026 release attributes $19.5 million of second-quarter RBR to acquisitions completed since 31 March 2025, and organic growth of 10.8% trailed the 15.7% headline rate. Third-quarter organic growth in the mid-single digits or lower would undercut the demand case.
- A large earnings move is priced in. Unusual Whales showed an options-implied earnings move of about 12.9% (about $20.33) on 9 October 2026, before the latest rise. A move of that size in either direction is within what the options market expected then.
Price setup
The 22 October 2026 adjusted close of $193.35 is the 52-week high, 0.0% below it. The prior 52-week high in the 9 October 2026 note was $185.58, so the shares have cleared that level. The 11 September 2026 weekly close of $149.93 was the low of the recent dip.
Crowding evidence is limited to what can be observed. The RSI is 84.0, the earnings date is 12 days away, and index-tracking demand is tied to the 27 October 2026 effective date. No SEC filings and no insider transactions appear in the records reviewed.
Catalysts, next 30 days
- 3 November 2026: Huron reports third-quarter 2026 results after the market close, with a conference call at 5:00 p.m. Eastern (company release, 20 October 2026). The report tests organic RBR growth after 10.8% in the second quarter and whether the $1.85–1.89 billion guide holds.
Elapsed catalysts
- 27 October 2026: effective date of the S&P index changes announced 22 October 2026, including the MSG Rangers addition to the S&P SmallCap 600. The date for Huron's own change is not separately stated in the headline. (passed 4d ago)
What would change the view
The case breaks if third-quarter organic RBR growth falls to the mid-single digits or lower while headline growth stays in double digits, or if Huron cuts RBR guidance below $1.85 billion. It also breaks on a daily close below $175, a level that would give back the move above the prior 52-week high of $185.58 by a clear margin.
A report that confirms organic growth near the second-quarter pace, together with guidance raised again, would strengthen the case. Analyst target increases above $193.35 after the report would show the Street marking estimates to the new price.
What it trades with
Huron sells consulting to healthcare, higher-education and commercial clients, and its shares have traded on the debate over whether AI tools substitute for consulting work. A Yahoo Finance article, "Huron Consulting Group (HURN) Slid Amid Concerns Over AI Disruption," reflects that debate. Index-linked flows after the S&P change may move the shares with other recent additions around 27 October 2026, independent of company news.
Notes
- Huron reports revenues before reimbursable expenses (RBR) separately from total revenue; its annual guidance uses RBR.
- Huron confirmed on 20 October 2026 that it reports third-quarter 2026 results on 3 November 2026 after the market close; earlier third-party dates of 27 October 2026 were wrong.